Sun Pharma Share Price Target 2025 : Brokerage firm Motilal Oswal has rated the performance of Sun Pharma stock and set a target price. It noted that the company's growth is fueled by specialty pipeline and branded market expansion. The brokerage said that growth in branded markets is expected to be driven by new launches, field force expansion and increased marketing spend. Sun Pharma aims to achieve consistent outperformance in India's branded business, the brokerage noted. The pipeline and field force scale-up are anticipated to drive growth in the specialty segment. The projected FY25-27 earnings CAGR is 14 per cent, led by a 17 per cent sales CAGR in specialty and 12 per cent in DF/EM markets, along with a 160bp margin expansion. Sun Pharma is valued at 32x 12M forward

See Full Page